PLRX Stock Plunges 89% in 3 Months: Here's What Investors Should Know

Shares of Pliant Therapeutics (PLRX) have plunged 88.5% in the past three months following recent setbacks in the clinical development program of its lead product candidate, bexotegrast (PLN-74809), for treating idiopathic pulmonary fibrosis (IPF). Bexotegrast is an oral, small-molecule, dual selective inhibitor of αvß6 and αvß1 integrins.IPF is the most prevalent and severe type of progressive pulmonary fibrosis, impacting around 150,000 patients in the United States and more than three million worldwide.P ...